导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.28% | 2128/4773 |
| 近一周 | -2.07% | 1164/5462 |
| 近一月 | -3.76% | 1944/5421 |
| 近一季 | -6.58% | 2139/5209 |
| 近半年 | -1.85% | 1708/4920 |
| 近一年 | 2.79% | 2049/4366 |
| 近两年 | 48.18% | 1532/2954 |
| 近三年 | 29.02% | 1091/2253 |
| 成立以来 | 107.46% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.26% 2739/4961 |
12.47% 2174/5312 |
- - |
- - |
| 2025 | 20.29% 2133/4813 |
0.59% 1809/3635 |
2.51% 1523/4076 |
16.32% 2669/4524 |
0.29% 2076/4813 |
| 2024 | 15.21% 953/3463 |
4.17% 477/2808 |
-1.78% 1107/3014 |
15.51% 1695/3129 |
-2.52% 2115/3463 |
| 2023 | -8.09% 980/2656 |
3.35% 1213/2280 |
-2.88% 699/2385 |
-1.76% 575/2515 |
-6.79% 1922/2655 |
| 2022 | -16.85% 520/2207 |
-10.86% 436/1919 |
7.57% 453/2016 |
-13.82% 978/2113 |
0.62% 1475/2208 |
| 2021 | -6.63% 1015/1822 |
-2.44% 640/1255 |
3.67% 962/1330 |
-6.79% 989/1466 |
-0.96% 1289/1822 |
| 2020 | 28.58% 559/1250 |
-9.15% 658/1028 |
12.95% 659/1067 |
11.29% 462/1164 |
12.60% 450/1184 |
| 2019 | 34.03% 417/1092 |
23.98% 535/754 |
0.18% 190/804 |
0.83% 455/850 |
7.03% 500/918 |
| 2018 | -21.77% 220/834 |
- - |
- - |
- - |
-11.64% 330/691 |
| 2017 | 26.52% 101/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 博时沪深300指数C VS. 长安沪深300非周期A(740101) |